IgGenix, Inc., a South San Francisco, CA-based biotechnology company focused on addressing allergic disease, raised $25m in Series A1 financing.
Khosla Ventures, which participated in IgGenix’s Series A funding in 2020, co-led the round along with Matthias Westman. New investors include Alexandria Venture Investments, ShangBay Capital and AllerFund.
The company intends to use the funds to further expand its discovery platform in food and nonfood allergies while accelerating its lead program into preclinical development.
Led by Chief Executive Officer Jessica Grossman, M.D., IgGenix is a biotechnology company that directly addresses food and other severe allergies by reengineering key antibodies involved in the allergic cascade.
Founded based on research by professors by Stephen Quake, D.Phil.; Kari Nadeau, M.D., Ph.D.; and Derek Croote, Ph.D. of Stanford University, the company isolates allergen-specific IgE antibodies and transforms them into IgG antibodies that alleviate and possibly prevent the allergic cascade.
FinSMEs
27/07/2021